Tuesday, July 1, 2025 7/1/2025

Plasmodium vivax Erythrocyte Invasion Mechanisms and Humoral Immune Response in Duffy Negative Africans

Award Number: R01AI162947
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/09/2022
PERIOD OF PERFORMANCE END DATE: 01/31/2027

Group Awards By:

View Award Description

Plasmodium vivax Erythrocyte Invasion Mechanisms and Humoral Immune Response in Duffy Negative Africans - PROJECT SUMMARY Title: Plasmodium vivax Erythrocyte Invasion Mechanisms and Humoral Immune Response in Duffy Negative Africans Individuals of African ancestry were thought to be protected from Plasmodium vivax because they lack Duffy antigen expression on the surface of their erythrocytes rendering P. vivax unable to invade their red blood cells. However, an increasing number of P. vivax cases reported across Africa and in Duffy-negative individuals challenges this conventional dogma, raising the possibility that some P. vivax lineages have evolved to use ligands other than Duffy Binding Protein for erythrocyte invasion. The intrinsic invasion mechanism and immune response of Duffy-negative individuals to P. vivax are largely unknown. In this application, we will investigate the expression and function of erythrocyte binding genes in Duffy-negative P. vivax and the antibody response of Duffy-negative individuals to P. vivax antigens. There are three specific aims: 1) to identify genes with differential expression between Duffy-positive and Duffy-negative P. vivax by RNA-seq; 2) to determine in vitro binding and invasion activities of P. vivax candidate ligand proteins to Duffy-negative red blood cells; and 3) to examine in vivo antibody levels to targeted P. vivax antigens associated with erythrocyte invasion in Duffy- negative patients. The proposed research will be conducted in Ethiopia, where malaria is a major public health problem and about 30% of the 1.2 million confirmed malaria cases were P. vivax. As our study sites have a large number of P. vivax cases and a significant proportion of Duffy-negative individuals, we have a unique opportunity to study the invasion mechanisms of P. vivax in Africa. We have a collaborative team and logistics in place for sample collection and processing. Our established lab culture facility closes to the health centers and successful P. vivax transcriptome data obtained from cultured schizonts have demonstrated the feasibility of this research. Comparison of P. vivax transcriptomes between Duffy-negative and Duffy-positive individuals from both in vitro and in vivo samples will provide the first description of genetic and functional attributes of P. vivax that permit infection of Duffy-negative erythrocytes. This research will significantly enhance the understanding of invasion mechanism of P. vivax in Duffy- negative individuals and lay a foundation for molecular and biochemical characterizations of P. vivax ligand-receptor interactions. Knowledge of P. vivax invasion mechanisms and host immune responses will have important implications for P. vivax vaccine development and vivax malaria risk assessment both within and outside Africa.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $644,879 )
2025	2025	DREXEL UNIVERSITY	3141 CHESTNUT ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	000	4	1/17/2025	NON-COMPETING CONTINUATION	$644,879
														Subtotal = $644,879

Issue Date FY: 2024 ( Subtotal = $755,430 )
2024	2024	DREXEL UNIVERSITY	3141 CHESTNUT ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	007	3	5/14/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$68,262
2024	2024	DREXEL UNIVERSITY	3141 CHESTNUT ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	003	3	2/14/2024	SUPPLEMENT FOR EXPANSION	$59,948
2024	2024	DREXEL UNIVERSITY	3141 CHESTNUT ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	002	3	2/13/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$627,220
2024	2024	DREXEL UNIVERSITY	3141 CHESTNUT ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Allergy and Infectious Diseases Research	006	3	4/3/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$673,191
2024	2023	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE, THE	9201 UNIVERSITY CITY BLVD	CHARLOTTE	NC	28223	MECKLENBURG	USA	Allergy and Infectious Diseases Research	004	2	4/3/2024	NON-COMPETING CONTINUATION	-$614,588
2024	2023	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE, THE	9201 UNIVERSITY CITY BLVD	CHARLOTTE	NC	28223	MECKLENBURG	USA	Allergy and Infectious Diseases Research	005	2	4/3/2024	SUPPLEMENT FOR EXPANSION	-$58,602
2024	2023	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE, THE	9201 UNIVERSITY CITY BLVD	CHARLOTTE	NC	28223	MECKLENBURG	USA	Allergy and Infectious Diseases Research	001	2	2/13/2024	SUPPLEMENT FOR EXPANSION	$0
2024	2023	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE, THE	9201 UNIVERSITY CITY BLVD	CHARLOTTE	NC	28223	MECKLENBURG	USA	Allergy and Infectious Diseases Research	000	2	2/13/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $755,430

Issue Date FY: 2023 ( Subtotal = $699,136 )
2023	2023	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE, THE	9201 UNIVERSITY CITY BLVD	CHARLOTTE	NC	28223	MECKLENBURG	USA	Allergy and Infectious Diseases Research	001	2	1/25/2023	SUPPLEMENT FOR EXPANSION	$60,861
2023	2023	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE, THE	9201 UNIVERSITY CITY BLVD	CHARLOTTE	NC	28223	MECKLENBURG	USA	Allergy and Infectious Diseases Research	000	2	1/11/2023	NON-COMPETING CONTINUATION	$638,275
														Subtotal = $699,136

Issue Date FY: 2022 ( Subtotal = $673,627 )
2022	2022	UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE, THE	9201 UNIVERSITY CITY BLVD	CHARLOTTE	NC	28223	MECKLENBURG	USA	Allergy and Infectious Diseases Research	000	1	2/9/2022	NEW	$673,627
														Subtotal = $673,627

Grand Total All Awards = $2,773,072

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Plasmodium vivax Erythrocyte Invasion Mechanisms and Humoral Immune Response in Duffy Negative Africans

Award Number: R01AI162947

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/09/2022

PERIOD OF PERFORMANCE END DATE: 01/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer